You are here

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Rituximab in psoriatic arthritis: an exploratory evaluation
  1. Esther Jimenez-Boj1,
  2. Tanja A Stamm1,
  3. Martina Sadlonova1,
  4. Jozef Rovensky2,
  5. Helena Raffayová2,
  6. Burkhard Leeb3,
  7. Klaus Peter Machold1,
  8. Winfried B Graninger4,
  9. Josef S Smolen1,5
  1. 1Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
  2. 2National Institute for Rheumatic Diseases, Piestany, Slovakia
  3. 32nd Department of Medicine – Lower Austrian Center for Rheumatology, State Hospital Stockerau, Stockerau, Austria
  4. 4Division of Rheumatology, Department of Medicine, Medical University of Graz, Graz, Austria
  5. 52nd Department of Medicine – Center for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
  1. Correspondence to Professor Josef S Smolen, Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria; josef.smolen{at}wienkav.at

Abstract

Background/objective Current therapies for psoriatic arthritis (PsA) comprise synthetic drugs and tumour necrosis factor inhibitors. In contrast, other biologicals including rituximab (RTX) are available for treating rheumatoid arthritis (RA). RTX is effective in autoantibody positive RA patients, although some efficacy has been reported in seronegative individuals. RTX has not yet been assessed in PsA. Therefore, an open label study of RTX in PsA was performed.

Patients and methods Nine patients with PsA and 14 with RA received RTX at 1000 mg twice within 14 days and were evaluated over 6 months.

Results A PsA response criteria response was attained in 56% of patients. DAS28 improved from 6.2 to 4.9 (medians) in PsA and 6.4 to 5.2 in RA, and Health Assessment Questionnaire from 1.5 to 1.0 and from 2.1 to 1.4, respectively (all p≤0.05). Disease Activity index for PSoriatic Arthritis changed from 52.0 to 32.5 (p<0.05); C reactive protein and Psoriasis Area and Severity Index did not change significantly. RTX was tolerated well.

Conclusions In this exploratory open study, RTX exhibited significant efficacy in PsA patients with long-standing disease. Thus, RTX may have efficacy in PsA warranting a randomised controlled clinical trial.

https://doi.org/10.1136/annrheumdis-2012-201897

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text